BACK
TO WEB VERSION
SUMMER/FALL
2003
Relief for Dry Eye
— Judy
Purdy
People with a disease called chronic dry eye now have
access to a new treatment based on research at the UGA College of Veterinary
Medicine.
Last December the U.S. Federal Drug Administration approved the drug
RESTASIS™ for chronic dry eye in humans. The prescription drug,
which became available in April, is based on UGA research conducted
by veterinary ophthalmologist Renee Kaswan.
Dry eye is characterized by an insufficient production of tears, which
lubricate the eye and remove foreign debris. Each year, an estimated
one million Americans experience symptoms caused by chronic dry eye.
The irritating and often painful condition can lead to serious cornea
damage.
“Dr. Kaswan’s invention reduces inflammation of the tear
ducts and enables them to resume their normal functions,” said
Rob Fincher, director of technology commercialization for the university’s
research foundation. “To my knowledge this is the first prescription
drug to go on the market that treats dry eye in people by allowing
the tear ducts to produce tears.”
Kaswan, a former UGA veterinary professor, first developed a treatment
for dry eye in dogs, where it is a common cause of blindness. The late
university bulldog mascot, Uga IV, was among the first dogs to benefit
from the canine treatment, which is now marketed in more than 35 countries.
While many prescription drugs are developed for people and later used
for dogs, “this may be the first time a drug has been developed
first for veterinary use and then tested and approved for use in human
patients,” Kaswan said.
For
more information, contact Rob Fincher at rrf@ovpr.uga.edu
|